Melbourne medical manufacturer Telix Pharmaceuticals has partnered with a major Japanese engineering company to market its TLX-250 imaging program for cancer patients. JFE Engineering is an expert of cyclotron infrastructure and radiopharmaceutical manufacturing, and has received clinical interest around the prospect for domestic production of new medical isotopes. Telix develops diagnostic and therapeutic products for … Continue reading VIC manufacturer targeting Japanese cancer treatment
Melbourne medical manufacturer Mesoblast has been named as the 2017 Global Technology Leader in the cell therapy industry. A biopharma company specialising in cell therapies, its has used its proprietary technology platform to establish one of the industry’s most clinically advanced and diverse portfolio of cell-based product candidates. It currently has three cell therapy product candidates … Continue reading Australian biopharma manufacturer named global leader
The US Food and Drug Administration (FDA) will review an antibiotic made by a Sydney medical manufacturer that fights life-threatening blood diseases. Recce is developing a new class of synthetic antibiotics used intravenously against E.coli and Staph bacteria in the blood, including their superbug forms. Following an application, Recce’s lead compound, RECCE 327, has been … Continue reading FDA considering ‘superbug’ drug manufactured in Sydney
Drug manufacturer IDT Australia has signed an Active Pharmaceutical Ingredient (API) Development agreement with the Victorian state government. The exact terms of the agreement have not been disclosure however an announcement has confirmed the deal will extend for 12 months, with IDT standing to receive more than $2 million from the project. The company has … Continue reading Australian drug manufacturer signs $2m government agreement
CSL Biotherapies, a subsidiary of CSL Limited Australia and one of the world’s leading manufacturers of influenza vaccine, has announced it has been awarded a contract by the United States Department of Health Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.